Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — Investor Presentation (July 2020)
35 slides from Lantern Pharma's investor presentation, Jul 1, 2020
Slide 1: Lantern Pharma Company Overview
Lantern Pharma Company Overview July 1, 2020 Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and Develop Targeted Cancer Therapies 1 Nasdaq: LTRN
Slide 2: Special Note Regarding Forward-Looking Statements
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this presentation
Slide 3: Lantern leverages A.I. to rescue and develop cancer therapies
Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development Failed or Abandoned Drug Assets RADR® Responders Non-Responders • Big data (genomic, clinical, response) • Patient stratification based on A.I. enabled Dru
Slide 4: Current oncology drug development is costly, risky, and inefficient
Current oncology drug development is costly, risky, and inefficient … a perfect problem area for artificial intelligence & machine learning Challenges in drug development … …are being met by data-driven, and A.I. approaches 3.4% $1B+ Average Avg. success rate of developmental cost oncology drugs per
Slide 5: Critical need to rescue failed drugs or bring abandoned assets to market
There is a critical need to rescue drugs that failed or bring abandoned therapeutic assets to market in order to create ROI for biopharma ROI Among The Top 12 Pharma – “... low efficacies of cancer drugs might be Continuous Decade of Decrease attributed to the heterogeneity of the tested 12 10.1 pat
Slide 6: Mega trends shaping drug development
Solving unmet needs and creating opportunities in personalizing cancer therapy by capitalizing on emerging technologies and industry trends Mega Trends Shaping Drug Development 1. Increased access to validated genomic & biomarker data 2. Increased sharing and collaboration globally among research gr
Slide 7: A.I.-driven drug discovery is a rapidly growing market
Drug discovery and development driven by A.I. is a rapidly growing market in response to fundamental shifts in the industry and a re-tooling of R&D Global A.I. Healthcare Market* 1200 $10B ~$4B 1000 800 A.I.-driven Drug Discovery/ Development market in 2024 600 400 200 $760M 0 2016 2024 *Source: Bio
Slide 8: Focus on oncology and owned therapeutic rights uniquely positions Lantern
Lantern’s focus on oncology, and advancing the portfolio where we own the therapeutic rights makes us uniquely positioned and differentiated Rapidly Accelerating Our Portfolio Value Scalable, Unique Artificial Intelligence Platform – RADR® 1. Guided the genetic signature to determine patient respons
Slide 9: Lantern's A.I. platform focused on predicting drug outcome and response
Lantern’s powerful A.I. platform is being developed with a pure focus on predicting drug outcome and drug response using a depth of interrelated biomarker and clinical data, including: • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation dat
Slide 10: Lantern's Unique & Rapidly Developing Pipeline
Lantern’s Unique & Rapidly Developing Pipeline Indication Drug R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Successfully partnered & out-licensed (Irofulven) for up to $14M Targeting for never-smoker population in Non-Small Cell Lung Cancer LP-300 NSCLC of Adenocarcinoma subtype
Slide 11: Patients annually worldwide and potential oncology therapy sales
Nearly 1 M patients annually worldwide with several Billion $USD in potential future oncology therapy sales 3 Drug Candidates in Development in Targeted Patient Segments With Clinical Need Ovarian, Pancreatic Non-Small Cell Lung Prostate Cancer Glioblastoma (GBM) & Liver Cancer Cancer (NSCLC) 1.3 mi
Slide 12: Overview of Lantern's Small Molecule Portfolio
Overview of Lantern’s Small Molecule Portfolio LP-100, Irofulven LP-300 LP-184 • DNA Damaging Agent • Disulfide bond disrupting agent • Novel DNA Damaging Agent - with cysteine modifying activity on member of the acylfulvene prodrug • Mediates cytotoxicity through select proteins (ALK) and class mul
Slide 13: LP-100 (Irofulven): out-licensed to Oncology Venture
LP-100 LP-100 (Irofulven): out-licensed to Oncology Venture and in an active, genetically-guided clinical trial for prostate cancer History of Safety, Tolerability & Efficacy in Multiple Clinical Trials Current status • Prior history in over 41 clinical trials spanning • Out-licensed to Oncology Ven
Slide 14: LP-100: Historical phase II trial results in prostate cancer
LP-100 LP-100 (Irofulven): Historical* phase II trial results in prostate cancer Median 1 yr. survival was 86% greater in Irofulven in combination treated metastatic Current Ongoing Precision Phase II Trial prostate cancer patients v. control 50 • Screening patients using Irofulven-specific 41 Irofu
Slide 15: LP-300 in development for female never-smokers with NSCLC
LP-300 LP-300 in development for female never-smokers with NSCLC adenocarcinoma based on strong historical data Mechanism of action Current status • Disulfide bond disrupting agent • Disrupts by covalently modifying cysteine • Inhibits and modulates activity of proteins in NSCLC pathways (ALK, EGFR,
Slide 16: Lung Cancer in Never-Smokers: a hidden but rising disease
LP-300 Lung Cancer in Never-Smokers (LCINS) – a hidden but rising disease Incidence of NSCLC in non-smokers in the U.K.* 28 • 7th leading cause of death among patients with solid tumors • More frequent in women with ~2/3 of patients with no % 13 reported smoking history • Adenocarcinoma is the most
Slide 17: LP-300 Phase III subgroup survival results
LP-300 Lantern’s precision oncology approach in the LP-300 Phase II trial will build on a prior Phase III trial that did not meet clinical efficacy endpoints but demonstrated survival benefit in a patient subgroup 72% LP-300 + Cisplatin/ Paclitaxel Placebo + Cisplatin/ Paclitaxel 63% 125% increase i
Slide 18: Female never-smokers showed clearest positive outcome in Phase III
LP-300 Female never-smokers showed the clearest statistically significant positive outcome among subgroups in the LP-300 treatment arm in advanced adenocarcinoma patients in Phase III 1.0 All females Survival probability 0.8 N = 114, HR = 0.579 1.0 (p value 0.0477) Female never-smokers 0.6 N = 66, 0
Slide 19: Proposed design for relaunching Phase II trial for LP-300
LP-300 Proposed design for relaunching of Phase II clinical trial for LP-300 in a targeted patient population Histology / Never-smoker NSCLC 40 – 75 demographic/ Adenocarcinoma patients stratified patients LP-300 + standard of care smoking history (Dosing every 3 weeks and Biomarker up to 8 treatmen
Slide 20: LP-184 for solid tumors and PTGR1 expressing cancers
LP-184 LP-184 for solid tumors and certain PTGR1 expressing cancers Unique Features Current status • Hydroxyurea Methylacylfulvene • 4 new patent filings: 2 new applications on synthetic manufacturing of new molecular entities & 1 new • Nanomolar potency across multiple solid tumor application on ge
Slide 21: LP-184 greater tumor regression in mouse model
LP-184 LP-184 treatment resulted in greater tumor regression in a mouse model with human cancer Treatment of Mice Engrafted with Human MV522 Multi-drug Resistant Tumor Cells 10 No Drug Relative Tumor Weight LP-100, 10 mg/kg LP-184, 10 mg/kg 1 LP-184, 20 mg/kg Drugs administered i.p. 3x a week for 3
Slide 22: Proposed LP-184 mechanism of action
LP-184 Proposed LP-184 mechanism of action based on acylfulvene drugs LP-184 Active Metabolite 1. Potential synergistic drug combinations due to involvement w/ DNA repair DNA Damage Induction pathway and Enzymatic Biotransformation Alkylation of DNA and adduct supported by gene Conversion of LP-184
Slide 23: LP-184 shows 10x-3,800x increase in in vitro potency
LP-184 LP-184 shows a 10x – 3,800x increase in in vitro potency over approved chemotherapeutics in various solid tumors 1,000,000 LP-184 Cisplatin Pemetrexed 100,000 Micromolar potency 10,000 IC50 [nM] 1,000 100 Nanomolar potency 10 1 SNU387_Liver H2228_NSCLC H1944_NSCLC OV90_Ovary NIHOVCAR3_Ovary C
Slide 24: LP-184 promise in Glioblastoma
LP-184 LP-184 shows significant promise in improving patient outcomes in Glioblastoma (GBM) – a rare cancer with median survival of < 1 year 500x – 13,000x increase in in-vitro potency LP-184 has a favorable CNS drug profile – over TMZ, (the current standard in GBM) blood brain barrier (BBB) permeab
Slide 25: RADR: robust and scalable platform for targeted cancer therapy
RADR® - A robust and scalable platform for accelerating the development of targeted cancer therapy, precision trials and Companion Dx Collaboration & Partner Data • Robust precision medicine/drug development Real World • Uncovering potential drug combinations Open Source & Published Data Internally
Slide 26: RADR identifies genetic markers and signatures for precision oncology
RADR® identifies genetic markers and signatures for precision oncology drug development, clinical response prediction and CDx enablement 80% Success in Blinded Predictions Output & Signature Development Process 13,200+ Oncology Patient Records & Response Information 144+ Drug-Tumor Interactions ~450
Slide 27: RADR Workflow Details
RADR® Workflow Details Uses machine learning methods to train on datasets Genetic Data Training Set Optimal model used on testing Tuned and Drug Sensitivity Data dataset Optimized Testing Predictive Set Response Model Gene Sets Parameter tuning and model development and evaluation Cancer Patient Pop
Slide 28: Our Intellectual Property Portfolio
Our Intellectual Property Portfolio – Extensive and continually growing position of over 108 issued and in-licensed patents and 7 patent applications across 14 patent families LP-300 Drug Sensitivity & 5 • In-licensed Response Signatures • Internally developed 108 families using Biomarkers Issued Pa
Slide 29: Studies & Collaborations With Top Tier Academic & Research Partners
Studies & Collaborations With Top Tier Academic & Research Partners 29 Nasdaq: LTRN
Slide 30: Heavy investment & investor interest in A.I. driven drug development
Heavy investment & investor interest in A.I. driven drug development Company Investment Valuation* Pipeline Status • Oncology Focus in 4 programs Jun. 2020 IPO $75+ Million • Ph. 2 – Prostate, Ph. 1 - NSCLC (NASDAQ: LTRN) $26 M. raised at IPO • Pre-Clin. – Solid Tumors & GBM • Funded through milesto
Slide 31: Value Building Milestones & Inflection Points
Value Building Milestones & Inflection Points Multiple Streams of Value Creation Foundational Year Launch Multiple Precision Trials Advance Platform Leverage Platform for Pharma Partners Prepare Trial Launches Secure Additional Compounds Prioritize Additional Compounds Readout for LP-100 Ph. 2 Secon
Slide 32: Cap Table
Cap Table LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 6,217,577 Warrants (WAEP $3.13) 262,003 Underwriter Warrants (Exercise Price at $18.75) 70,000 Options (Employees, Management and Directors) 820,605 Fully Diluted Shares Outstanding 7,370,185 • Management and Directors own ~51% of fully
Slide 33: Highly experienced in innovation for pharma, drug development & oncology
Highly experienced in innovation for pharma, drug development & oncology Management Team Board of Directors Jeff Donald Keyser, Ph.D., J.D., MPA Panna Sharma President & CEO • Board Chairman • Former President & CEO at Cancer Genetics (Nasdaq: CGIX) • Founder of Renibus Therapeutics and ZSPharma • L
Slide 34: Investment Highlights
Investment Highlights - Lantern Pharma has a unique, growing and validated foundation for the future of cancer therapy and patient care Active drug rescue process and in the clinic with 2 LP-300 submitted for Orphan Disease Designation and compounds and accelerating additional compounds LP-184 to be
Slide 35: Lantern Pharma - Thank you!
Lantern Pharma Company Overview Thank you! July 1, 2020 35 Nasdaq: LTRN